Blood pressure. Supplement最新文献

{"title":"Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. the QoLaN study.","authors":"M. Hermans, O. De Coster, L. Seidel, A. Albert, P. van de Borne","doi":"10.1080/08037050903109523","DOIUrl":"https://doi.org/10.1080/08037050903109523","url":null,"abstract":"BACKGROUND\u0000Nebivolol is a highly selective beta-adrenoreceptor antagonist with vasodilating properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) in real life conditions. In total, 1468 patients were enrolled, 12% diabetics. Nebivolol was prescribed as monotherapy, add-on or switch medication.\u0000\u0000\u0000METHODS\u0000In this open-label, prospective study, the JNC-VII BP target values were used: < 140/90 and < 130/80 mmHg for diabetics. The responder rate and the QoL was determined at baseline and after 4 and 8 weeks.\u0000\u0000\u0000RESULTS\u0000After 4 weeks, 27% of subjects reached target BP, 45% after 8 weeks. The responder rates were 92, 90 and 83% for the monotherapy, add-on and switch groups. Compared with baseline, all showed statistical significance at 8 weeks. Similarly to results for the QoL after 8 weeks, the mean improvement in QoL for all three groups was 9-10 points (total range: 0-88).\u0000\u0000\u0000CONCLUSIONS\u0000The study demonstrates that nebivolol in mild to moderate hypertension is associated with overall improvements in QoL, with a marked BP-lowering effect, in monotherapy, add-on or switch, irrespective of the glucose tolerance status. It may be hypothesized that its dual mode of action explains its BP-lowering effect as well as the tolerability.","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"63 1","pages":"5-14"},"PeriodicalIF":0.0,"publicationDate":"2009-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83777773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. the QoLaN study.","authors":"Michel P Hermans,&nbsp;Olivier De Coster,&nbsp;Laurence Seidel,&nbsp;Adelin Albert,&nbsp;Philippe Van de Borne","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Nebivolol is a highly selective beta-adrenoreceptor antagonist with vasodilating properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) in real life conditions. In total, 1468 patients were enrolled, 12% diabetics. Nebivolol was prescribed as monotherapy, add-on or switch medication.</p><p><strong>Methods: </strong>In this open-label, prospective study, the JNC-VII BP target values were used: < 140/90 and < 130/80 mmHg for diabetics. The responder rate and the QoL was determined at baseline and after 4 and 8 weeks.</p><p><strong>Results: </strong>After 4 weeks, 27% of subjects reached target BP, 45% after 8 weeks. The responder rates were 92, 90 and 83% for the monotherapy, add-on and switch groups. Compared with baseline, all showed statistical significance at 8 weeks. Similarly to results for the QoL after 8 weeks, the mean improvement in QoL for all three groups was 9-10 points (total range: 0-88).</p><p><strong>Conclusions: </strong>The study demonstrates that nebivolol in mild to moderate hypertension is associated with overall improvements in QoL, with a marked BP-lowering effect, in monotherapy, add-on or switch, irrespective of the glucose tolerance status. It may be hypothesized that its dual mode of action explains its BP-lowering effect as well as the tolerability.</p>","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"1 ","pages":"5-14"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28625704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of four automatic devices for self-measurement of blood pressure according to the International Protocol: the Pic Indolor Personal Check, Comfort Check, My Check and Travel Check.","authors":"Giuseppe Germano,&nbsp;Angelos Psimenos,&nbsp;Francesco Sarullo,&nbsp;Alessandro Venditti,&nbsp;Valerio Pecchioli,&nbsp;Roland Asmar","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Four oscillometric devices for self-measurement of blood pressure (SBPM) were evaluated according to the International Protocol of the European Society of Hypertension (ESH) in four separate studies. The Pic Indolor Personal Check, Comfort Check and My Check measure blood pressure (BP) at the brachial level; the Travel Check measures radial BP at the wrist level.</p><p><strong>Methods: </strong>The International Protocol includes a total number of 33 subjects. In each study and for each subject, four BP measurements were performed simultaneously by two observers using mercury sphygmomanometers alternately with three measurements by the tested device. The difference between the observers and the device BP values (99 pairs) were classified into three categories (< or =5, < or =10, < or =15 mmHg).</p><p><strong>Results: </strong>All four tested devices passed the validation process. The mean differences between the device and mercury readings were 0.1 +/- 2.9 and -0.1 +/- 3.8 mmHg for systolic and diastolic BP respectively for the Personal Check; -1.0 +/- 3.7 and 0.2 +/- 3.2 mmHg for the Comfort Check; -0.6 +/- 4.5 and -1.5 +/- 4.3 mmHg for the My Check; -0.1 +/- 2.0 and 0.6 +/- 1.7 mmHg for the Travel Check.</p><p><strong>Conclusion: </strong>Readings of the Pic Indolor Personal Check, Comfort Check, My Check and Travel Check devices differing by less than 5, 10 and 15 mmHg fulfill the International Protocol requirements and therefore can be used by patients for SBPM.</p>","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"1 ","pages":"15-23"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28625705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical aspects in hypertension diagnosis and treatment.","authors":"Thomas Hedner,&nbsp;Krzysztof Narkiewicz,&nbsp;Suzanne Oparil,&nbsp;Sverre Kjeldsen","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"1 ","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28625703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan.","authors":"Derek Weycker,&nbsp;Abdulkadir Keskinaslan,&nbsp;Drew Griffin Levy,&nbsp;John Edelsberg,&nbsp;Alex Kartashov,&nbsp;Gerry Oster","doi":"10.1080/08038020802316536","DOIUrl":"https://doi.org/10.1080/08038020802316536","url":null,"abstract":"<p><strong>Objective: </strong>To describe the real-world effectiveness of amlodipine add-on therapy for hypertensive patients receiving valsartan.</p><p><strong>Methods: </strong>Retrospective cohort study based on USA electronic medical records. The study population included hypertensive patients who, between January 1998 and December 2005, were receiving valsartan and subsequently initiated add-on therapy with amlodipine. Change in systolic blood pressure (SBP)/diastolic blood pressure (DBP), and attainment of goal SBP/DBP (i.e. < 140/90 mmHg), were examined based on last available reading prior to day 180 following initiation of amlodipine.</p><p><strong>Results: </strong>Mean (+/- SD) baseline SBP/DBP of study subjects (n=155) was 152.5 (+/- 21.1)/84.0 (+/- 13.5) mmHg. Add-on therapy with amlodipine reduced SBP by 13.3 mmHg (95% CI 9.4-17.1) and DBP by 6.1 mmHg (95% CI 4.2-8.1). Among patients with baseline SBP/DBP > or = 160/100 mmHg (n=69), corresponding reductions were 28.8 mmHg (95% CI 23.4-34.2) and 11.4 mmHg (95% CI 8.4-14.3). Goal SBP/DBP was achieved by 46% (95% CI 37.7-55.6) of subjects; rates of goal attainment were similar for patients with and without diabetes or chronic kidney disease, and those aged > or = 65 years versus younger.</p><p><strong>Conclusions: </strong>Adding amlodipine to valsartan for treatment of hypertension results in clinically meaningful reductions in blood pressure, on an overall basis and in high-risk subgroups who may benefit the most from blood pressure control.</p>","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"2 ","pages":"5-12"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08038020802316536","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27975678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.","authors":"Gerd Bönner","doi":"10.1080/08038020802519220","DOIUrl":"https://doi.org/10.1080/08038020802519220","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy and tolerability of candesartan cilexetil 32 mg in combination with hydrochlorothiazide (HCT) 12.5 mg or 25 mg in hypertensive patients not optimally controlled with candesartan monotherapy.</p><p><strong>Patients and methods: </strong>A total of 3521 patients with treated or untreated hypertension and sitting diastolic blood pressure (DBP) 90-114 mmHg, entered a single-blind run-in phase with candesartan (16 mg for 2 weeks, followed by 32 mg for 6 weeks). At the end of the run-in phase, 1975 patients who still had DBP 90-114 mmHg were randomized to 8 weeks' double-blind treatment with either candesartan 32 mg (n=654), or candesartan-HCT 32/12.5 mg (n=656), or candesartan-HCT 32/ 25 mg (n=665).</p><p><strong>Principal results: </strong>At randomization, the mean blood pressure was similar in the three treatment groups (approximately 153/97 mmHg). It was reduced during the double-blind treatment phase by 6.1/5.6 mmHg in the candesartan 32 mg group, by 13.0/8.8 mmHg in the candesartan-HCT 32/12.5 mg group, and by 15.5/10.0 mmHg in the candesartan-HCT 32/25 mg group (p<0.01 for all between treatment comparisons). All study treatments were generally well tolerated.</p><p><strong>Conclusion: </strong>Candesartan-HCT 32/12.5 mg and candesartan-HCT 32/25 mg are highly effective and provide improved blood pressure reduction and blood pressure control relative to candesartan 32 mg monotherapy, with maintained tolerability, in hypertensive patients whose blood pressure is not optimally controlled with candesartan monotherapy. Furthermore, candesartan-HCT 32/25 mg is more effective than candesartan-HCT 32/12.5 mg in this population.</p>","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"2 ","pages":"22-30"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08038020802519220","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27974149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders.","authors":"Georg Nickenig,&nbsp;Vladimir Simanenkov,&nbsp;Giuseppe Lembo,&nbsp;Pablo Rodriguez,&nbsp;Thomas Salko,&nbsp;Shannon Ritter,&nbsp;Jack Zhang","doi":"10.1080/08038020802507290","DOIUrl":"https://doi.org/10.1080/08038020802507290","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy, safety and tolerability of a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT) in patients with hypertension and an inadequate BP response to aliskiren monotherapy (mean sitting diastolic BP [msDBP] > 90 and < or = 110 mmHg following 4 weeks of aliskiren 300 mg).</p><p><strong>Methods: </strong>In this study, 880 patients with hypertension and an inadequate BP response to aliskiren monotherapy were randomized to once-daily, double-blind treatment with a single-pill combination of aliskiren/HCT 300/25 mg or 300/12.5 mg, or aliskiren 300 mg monotherapy. At the week 8 endpoint, least-squares mean changes in mean sitting systolic/diastolic BP (msSBP/DBP) from baseline were analyzed for the intent-to-treat population.</p><p><strong>Results: </strong>Aliskiren/HCT 300/25 mg and 300/12.5 mg provided significantly greater msSBP/DBP reductions from baseline (15.9/11.0 mmHg and 13.5/10.5 mmHg, respectively) than aliskiren 300 mg alone (8.0/7.4 mmHg; both p<0.001). Rates of BP control (<140/90 mmHg) were significantly higher with aliskiren/HCT 300/25 mg (60.2%) and 300/12.5 mg (57.9%) than with aliskiren 300 mg alone (40.9%; both p<0.001). Aliskiren/HCT single-pill combination treatment showed similar tolerability to aliskiren monotherapy.</p><p><strong>Conclusions: </strong>Aliskiren/HCT single-pill combinations provide clinically significant additional BP reductions and improved BP control rates over aliskiren alone in patients who are non-responsive to aliskiren 300 mg monotherapy.</p>","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"2 ","pages":"31-40"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08038020802507290","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27974150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More focus on therapeutic targets and improved tolerability in hypertension.","authors":"Thomas Hedner,&nbsp;Sverre E Kjeldsen,&nbsp;Krzysztof Narkiewicz,&nbsp;Susanne Oparil","doi":"10.1080/08038020802571775","DOIUrl":"https://doi.org/10.1080/08038020802571775","url":null,"abstract":"During recent years, there have been increased efforts in most countries to improve management of hypertensive patients in order to reduce cardiovascular morbidity and mortality in the population. According to current recommendations of management of hypertension, about three-quarters of those over the age of 65 years, more than half of those aged over 55 years, and about one-third of adults over 16 years of age are considered hypertensive (1–3). When non-pharmacological efforts are insufficient, a large proportion of the adult population will therefore, according to current guidelines, require pharmacological intervention to lower blood pressure (1–3). Numerous studies performed in many countries around the world have repetitively shown that adequate blood pressure control is achieved and maintained only in a limited proportion of the hypertensive population (1,2). Compared with those with lower blood pressure levels, treated patients with a blood pressure of 140 and/or 90 mmHg or more will be at excess cardiovascular risk and more likely to suffer negative health consequences. Poor control of hypertension therefore remains an important issue and deserves considerably more focus as well as increased efforts from the medical community. One important reason for poor hypertension control seems to be that many physicians often base antihypertensive treatment on monotherapy, although there may be a clear need for add-on therapy (4). In the current issue of Blood Pressure, the topic of combination therapy is addressed in a series of communications. Weycker et al. (5) present data from a large database survey showing the effectiveness of add-on treatment with amlodipine to obtain an improved systolic and diastolic blood pressure reduction in patients on valsartan monotherapy. Trenkwalder et al. (6), also studying amlodipine and valsartan, find that the combination lowers blood pressure in patients not controlled by an angiotensin-converting enzyme inhibitor/calcium-channel blocker combination. Nickenig and coworkers (7) find that the fixed combination of aliskiren/hydrochlorothiazide (HCTZ) more effectively lowers blood pressure in aliskiren non-responders with a similar tolerability. Börner et al. (8) describe the effectiveness of a candesartan/HCTZ combination providing an improved blood pressure reduction compared with candesartan monotherapy with maintained tolerability. Taken together, in patients with insufficient hypertension control on monotherapy with an angiotensin 1 receptor antagonist or a renin inhibitor, combination with a calcium antagonist or HCTZ will provide an improved control and a maintained tolerability. These data are in agreement with data from a previous meta-analysis (9) of a large series of randomized, double-blind, placebo-controlled antihypertensive combination trials, demonstrating that combination therapy improves antihypertensive efficacy as well as tolerability. Combination therapy produces an additive effect of the blo","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"2 ","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08038020802571775","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27974148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.","authors":"P Trenkwalder,&nbsp;R Schaetzl,&nbsp;E Borbas,&nbsp;R Handrock,&nbsp;S Klebs","doi":"10.1080/08038020802488855","DOIUrl":"https://doi.org/10.1080/08038020802488855","url":null,"abstract":"<p><strong>Aims: </strong>This multicenter, open-label, single-arm trial assessed the efficacy of the combination of amlodipine 10 mg and valsartan 160 mg to provide additional blood pressure reduction and tolerability in patients with moderate hypertension not adequately responding to the combination of ramipril 5 mg and felodipine 5 mg.</p><p><strong>Results: </strong>Of 133 patients treated for 5 weeks with ramipril 5 mg and felodipine 5 mg, 105 failed to achieve mean sitting systolic blood pressure <140 mmHg. These non-responders were then treated for an additional 5 weeks with amlodipine 10 mg and valsartan 160 mg, which resulted in clinically and statistically significant additional reductions in mean sitting systolic blood pressure of 15.4 mmHg (p<0.0001) and mean sitting diastolic blood pressure of 7.0 mmHg (p<0.0001). Adverse event rates were low with both treatment regimens.</p><p><strong>Conclusions: </strong>In hypertensive patients not controlled at 5 weeks by ramipril 5 mg and felodipine 5 mg, significant additional blood pressure reductions were observed after 5 weeks of treatment with amlodipine 10 mg and valsartan 160 mg. The combination of amlodipine 10 mg and valsartan 160 mg was well tolerated.</p>","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"2 ","pages":"13-21"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08038020802488855","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27975679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension.","authors":"Kwo-Chang Ueng,&nbsp;Lung-Chun Lin,&nbsp;Wen-Chol Voon,&nbsp;Ming-Cheng Lin,&nbsp;Yen-Bin Liu,&nbsp;Ho-Ming Su,&nbsp;Po-Yuan Chang,&nbsp;Tsung-Hsien Lin,&nbsp;Wei-Liang Chen,&nbsp;Chau-Chung Wu,&nbsp;Wen-Ter Lai,&nbsp;Chung-Sheng Lin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Aims: </strong>This study sought to compare the antihypertensive efficacy and tolerability of a fixed-dose combination with amlodipine/benazepril with that of amlodipine monotherapy in Chinese hypertensive subjects.</p><p><strong>Results: </strong>This multicenter, double-blind, 8-week study randomized 111 patients to fixed-dose amlodipine besylate/benazepril HCl (2.5/5 mg/day titrated to 5/10 mg/day as needed at week 4 to reach goal blood pressure (BP) <140/90 mmHg) or amlodipine besylate monotherapy (5 mg/day titrated to 10 mg/day as needed). At week 8, patients randomized to combination therapy compared with monotherapy had a comparable BP control rate (56.0% vs. 46.2%; p = 0.32). Fixed-dose combination resulted in similar reductions in sitting systolic (SBP) and diastolic BP (DBP) compared with monotherapy (SBP: -19.3 +/- 12.5 vs. -20.9 +/- 13.3 mmHg; DBP: -9.2 +/- 10.4 vs. -11.3 +/-9.3 mmHg; both p=NS). Safety profiles did not differ between groups, but cough was more common in the combination group (11.0% vs. 0%; p = 0.013).</p><p><strong>Conclusions: </strong>In this group of patients, comparable antihypertensive effects were seen with the fixed-dose combination therapy, compared with amlodipine monotherapy. Both treatments appeared well tolerated in the studied population, but cough was more common in the fixed-dose combination group.</p>","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"1 ","pages":"24-31"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27599099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}